viewTRACON Pharmaceuticals

Full interview: TRACON Pharmaceuticals to release important data points on its wet AMD therapy in first half of 2020

TRACON Pharmaceuticals (NASDAQ:TCON) CEO Charles Theuer tells Proactive the biotech that develops therapies to treat cancer and ophthalmic diseases is expecting top-line data from its Phase 2 AVANTE trial of DE-122 in patients with wet AMD in the first half of 2020.

Separately, Theur says he was really excited to hear when a member of TRACON’s Scientific Advisory Board Dr. William Kaelin, was awarded the Nobel Prize for Physiology or Medicine one week ago.

Quick facts: TRACON Pharmaceuticals

Price: 2.3 USD

Market: NASDAQ
Market Cap: $12.65 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...



TRACON Pharmaceuticals looks forward to positive Phase 2 cancer trial data...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive its corporate partners will present positive data from a Phase 2 cancer trial of the drug envafolimab at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. Theuer says the trial enrolled...

2 weeks, 3 days ago

2 min read